Clearside Biomedical, Inc. (CLSDQ)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
Developing Drug Therapies to Treat Blinding Diseases of The Eye	1.66M	8.23M	1.33M	29.58M	7.89M
Developing Drug Therapies to Treat Blinding Diseases of The Eye Growth	-79.77%	519.89%	-95.51%	274.65%	263.28%
Total	1.66M	8.23M	1.33M	29.58M	7.89M
Total Growth	-79.77%	519.89%	-95.51%	274.65%	263.28%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015
United States	1.66M	8.23M	1.33M	29.58M	7.89M
United States Growth	-79.77%	519.89%	-95.51%	274.65%	263.28%
Total	1.66M	8.23M	1.33M	29.58M	7.89M
Total Growth	-79.77%	519.89%	-95.51%	274.65%	263.28%

Data Source: S&P Global Market Intelligence Last updated: Sep 30, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 28, 2026

Data Sources Report a data error